National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

STATUTORY RULES

1971 No.

___________

 

REGULATIONS UNDER THE NATIONAL HEALTH ACT 1953-1971.*

WHEREAS it is provided by sub-section (4.) of section 101 of the National Health Act 1953-1971 that a drug or medicinal preparation that was not a pharmaceutical benefit under the National Health Act 1953-1958 immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS that Committee has recommended to the Minister that the following drugs and medicinal preparations be prescribed as pharmaceutical benefits under section 85 of the National Health Act 1953-1971, namely, the drugs and medicinal preparations proposed to be inserted in the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations by regulation 4 and the Third Schedule to these Regulations:

NOW THEREFORE I, the Governor-General in and over the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953-1971.

Dated this twenty sixth day of November, 1971.

Paul Hasluck

Governor-General.

By His Excellency’s Command,

(Sgd) “Ken Anderson”

Minister of State for Health.

________

 

Amendments of the National Health (Pharmaceutical Benefits) Regulations 

Commencement.

1. These Regulations shall come into operation on the first day of December, 1971.

First Schedule.

2. The First Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the First Schedule to these Regulations.

Second Schedule.

3. The Second Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Second Schedule to these Regulations.

Third Schedule.

4. The Third Schedule to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in the Third Schedule to these Regulations.

____________________________________________________________________________________

* Notified in the Commonwealth Gazette on 1971.

  Statutory Rules 1960, No. 17, as amended to date. For previous amendments of the National Health (Pharmaceutical Benefits) Regulations see footnote   to Statutory Rules 1971, No. 44 and see also Statutory Rules 1971, Nos. 44, 101, and.

22171/71—Price 20c 12/18.11.1971

Fifth Schedule.

5. The Fifth Schedule to the National Health (Pharmaceutical Benefits) Regulations is repealed and the fol lowing Schedule inserted in its stead:—

FIFTH SCHEDULE Regulation 14.

Pharmaceutical Benefits the Prescribing or Which is Subject to Conditions and Restrictions

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
1	Acetylcysteine.............................................	Cystic Fibrosis (mucoviscidosis)
2	(1) Aspirin with Paracetamol and Caffeine Tablets	Any disease or condition in a pensioner
(2) Aspirin with Codeine Phosphate and Pentobarbitone Sodium Tablets
3	Acrylic Resin...............................................	Ileostomy or colostomy conditions
4	Albumaid XP...............................................	With the written authority of the Director-General, Phenylketonuria
5	Aldosterone.................................................	With the written authority of the Director-General, treatment of an acute crisis in adrenal cortical hypofunction (including Addison’s disease and salt-losing congenital adrenal hypoplasia)
6	Alprenolol Hydrochloride Injection	Idiopathic hypertrophic subaortic stenosis
Right ventricular outllow tract obstruction
Dissecting aneurysm, aortic
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis
7	Alprenolol Hydrochloride Tablets	With the written authority of the Director-General—
Idiopathic hypertrophic subaortic stenosis Right ventricular outflow tract obstruction Dissecting aneurysm, aortic
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis
8	Amantadine Hydrochloride.......................	With the written authority of the Director-General, the treatment of Parkinson’s disease caused otherwise than by treatment with a drug
9	Ambenonium Chloride...............................	Myasthenia gravis
10	Aminocaproic Acid.....................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
11	Aminogran....................................................	With the written authority of the Director-General, phenylketonuria
12	Aminosalicylic Acid...................................	Tuberculosis
13	Amphotericin B injection..........................	Systemic mycoses
14	(1) Ampicillin Capsules, B.P.....................	Infections by susceptible organisms when these
(2).Ampicillin Injections, Tablets, Suspensions and Syrups	cannot be safely and effectively treated with sulphonamides, phenoxymethyl penicillin or phenethicillin
Urinary tract infections where sulphonamide treatment has proved ineffective and where positive bacteriological evidence shows the organism to be sensitive to ampicillin or where the patient is sensitive to sulphonamides

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
14—cont.	Broad spectrum antibiotic treatment of patients undergoing steroid therapy or recently subjected to steroid therapy
Bacterial endocarditis
Meningitis
15	Ascorbic Acid Tablets, B.P.......................	Any disease or condition in a pensioner
16	Azathioprine................................................	With the written authority of the Director-General, azathioprine therapy for a person who has been discharged from an approved hospital and received that therapy while a patient in the hospital
17	Benzathine Penicillin, B.P.........................	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)
18	Benzoin Compound Tincture, B.P.C. aerosol spray	Ileostomy or colostomy conditions
19	Benzylpenicillin Injection, 5,000,000 units	Bacterial endocarditis or septicaemia
20	(1) Benzylpenicillin Tablets, B.P.	Prophylaxis of recurrent streptococcal infections, (including rheumatic fever)
(2) Benzylpenicillin Capsules..................
21	Benzylpenicillin Injection, 10,000,000 units	Bacterial endocarditis or septicaemia
Gastrointestinal surgery
22	(1) Benzylpenicillin with Streptomycin Sulphate	Endocarditis due to streptococcus faecalis or streptococcus viridans
(2) Benzylpenicillin with Procaine Penicillin and Streptomycin Sulphate
23	Betahistine Hydrochloride.........................	Meniere’s Syndrome
24	Betamethasone Acetate and Betamethasone Injection	Intra-articular use
		With the written authority of the Director-General, pro-operative and post-operative prophylactic therapy for those patients undergoing or recently subjected to steroid therapy
25	Busulphan Tablets, B.P..............................	Treatment in malignant neoplasia
26	(1) Calciferol Tablets, Strong, B.P...........	Any disease or condition in a pensioner
(2) Calciferol, B.P.......................................	With the written authority of the Director-General—
Hypoparathyroidism
Osteomalacia following gastrectomy
Vitamin D-resistant rickets
27	Calcium Aminosalicylate..........................	Tuberculosis
28	Capreomycin Sulphate..............................	Tuberculosis
29	Carbamazepine...........................................	Epilepsy
Trigeminal neuralgia
30	Carbenicillin Sodium.................................	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that carbenicillin is the most appropriate therapeutic agent
31	Carbenoxolone Sodium.............................	Any disease or condition in a patient receiving treatment in or at an approved hospital
With the written authority of the Director-General, gastric ulcer where a radiological examination or other appropriate tests have confirmed the presence of a gastric ulcer
32	Cephalexin Monohydrate.........................	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that cephalexin monohydrate is the most appropriate therapeutic agent
33	Cephaloridine..............................................	With the written authority of the Director-General, infections where positive bacteriological evidence confirms that cephaloridine is the most appropriate therapeutic agent
34	Cephalothin Sodium...................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
35	Ceratonia......................................................	Oesophageal reflux in infants
36	Charcoal Tablets.........................................	Ileostomy or colostomy conditions

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
37	Chlorambucil Tablets, B.P........................	Treatment in malignant neoplasia
38	Chloramine Deodorant Tablets and powder	Ileostomy or colostomy conditions
39	(1) Chloramphenicol Capsules, B.P.........	Bacterial meningitis
(2) Chloramphenicol Injections...............	Intraocular infections
(3) Chloramphenicol Oral Suspension	Rickettsioses
	Typhoid
The treatment of other serious infections in a patient where it is established by appropriate bacteriological testing that Chloramphenicol is the only suitable antibiotic listed as a pharmaceutical benefit for use in treating the infection in the palient
40	Chlorotrianisene Tablets............................	Carcinoma of the prostate
41	(1) Chlorpromazine Hydrochloride B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Chlorpromazine Injection, B.P.	Major psychoses including—
(3) Chlorpromazine Tablets, B.P.	Major organic psychoses
Manic psychoses
Paranoid states
Schizophrenia
42	Cholestyramine...........................................	With the written authority of the Director-General—
Bile salt malabsorption associated with ileal resection or proven ileal disease
Pruritis associated with partial biliary obstruction not responding to other therapy
Initial treatment with cholestyramine of proven hyperbetalipoproteinaemia (type II) not responding to other therapy
A second or subsequent course of treatment for proven hyperbetalipoproteinaemia (type II) in patients who respond to treatment with cholestyramine but do not respond to other therapy
43	Clofibrate.....................................................	With the written authority of the Director-General—
Diabetic retinopathy (exudative)
Initial treatment with clofibrate of hyperlipidemia not responding to dietary therapy
A second or subsequent course of treatment for hyperlipidaemia where significant lowering of serum cholesterol subsequent to initial treatment with clofibrate has been established by laboratory report
44	(1) Cloxacillin Sodium, B.P......................	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Cloxacillin Capsules, B.P.
With the written authority of the Director-General, serious infections where bacteriological evidence confirms the presence of penicillinase-producing staphylococci
45	(1) Codeine Phosphate with Aspirin Soluble Tablets	Any disease or condition in a pensioner
(2) Codeine Phosphate with Aspirin Tablets
(3) Codeine Phosphate with Aspirin and Paracetamol Soluble Tablets
(4) Codeine Phosphate with Aspirin and Paracetamol Tablets
(5) Codeine Phosphate with Aspirin, Paracetamol and Caffeine Tablets
46	Colistin Sulphomethate Sodium, B.P., for injection	Pyocyaneus infection, other gram-negative infections where no other drug is effective
47	Cyanocobalamin Injection, B.P................	Pernicious anaemia and other proven Vitamin B-12 deficiencies

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
47—cont.	Post gastrectomy treatment
	Sub-acute combined degeneration of the cord
	Neuroblastoma
48	Cycloserine Capsules, B.P.........................	Tuberculosis
49	Cymogran.....................................................	With the written authority of the Director-General, phenylketonuria
50	(1) Cyproheptadine Hydrochloride, B.P.	Allergic rhinitis
		Allergic dermatoses
(2) Cyproheptadine Tablets, B.P.	Migraine
51	Cytosine Arabinoside Hydrochloride	Any disease or condition in a patient receiving treatment in or at an approved hospital
52	Deodorant Detergent Solution (Lauryldiniethyl Benzyl Ammonium Chloride and ‘TERIC’ N8)	Ileostomy or colostomy conditions
53	(1) Deoxycortone Acetate Injection, B.P.	Adrenal cortical hypofunction including Addison’s disease
(2) Deoxycortone Acetate Implants, B.P.	Total adrenalectomy
(3) Deoxycortone Acetate
54	Desferrioxamine Mesylate........................	Acute iron poisoning
Hepatolenticular degeneration
55	(1) Dextromoramide Tablets, B.P.	Treatment in malignant neoplasia
(2) Dextromoramide Tartrate, B.P.
56	Dextrose Polymer.......................................	With the written authority of the Director-General, phenylketonuria
57	(1) Diazepam, B.P., Syrup........................	Any disease or condition in a pensioner
(2) Diazepam Tablets, B.P........................	Any disease or condition in a patient receiving treatment in or at an approved hospital
The treatment of a mental disorder in a patient discharged from an approved hospital at which he received treatment for a mental disorder
Epilepsy
Hereditary chorea (Huntington’s)
Malignant neoplasia (late stage)
Motor neurone lesion
Multiple sclerosis
Radiation sickness
Stiff-man syndrome
58	Diazoxide.....................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
59	Dicyclomine Hydrochloride with Doxylamine Succinate and Pyridoxine Hydrochloride	Vomiting in pregnancy
60	Dienoestrol Cream.....................................	Any disease or condition in a pensioner
61	(1) Dihydroergotoxine Mesylate Tablets	For the treatment of patients who have suffered an attack of paralytic poliomyelitis
(2) Dihydroergotoxine Mesylate Injection
62	Dihydrotachysterol....................................	Hypoparathyroidism
63	Dimethicone Aerosol Spray.....................	Ileostomy or colostomy conditions
64	Dimethicone Creams.................................	Use with surgical appliances.
65	(1) Dioctyl Sodium Sulphosuccinate	Any disease or condition in a pensioner
(2) Dioctyl Sodium Sulphosuccinate with Danthron
66	Disodium Cromoglycate...........................	With the written authority of the Director-General, the prevention of attacks of asthma in the case of a patient whose attacks of asthma have been sufficiently severe and frequent to interfere seriously with his normal activities of life and whose recurrences of asthma—
(a)were not controlled by adequate use of bronchodilators and other recognized methods of prevention and treatment; or

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
66—cont.	(b) required the continuous use of corticosteroid therapy
67	Droperidol.....................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
68	Epicillin.........................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
69	Ethacrynic Acid...........................................	Fluid retention associated with heart failure, cirrhosis of the liver or nephrotic syndrome
Fluid retention associated with other conditions and not responding to thiazides
70	Ethinyloestradiol Tablets, B.P..................	Any disease or condition in a pensioner
Carcinoma of the breast post-menopausal
Carcinoma of the prostate
Hereditary telangiectasis
Premature menopause that is surgically induced
Turner’s syndrome
71	Ethionamide................................................	Tuberculosis
72	Ethisterone Tablets, B.P.............................	Turner’s syndrome
73	Ethyloestrenol..............................................	With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
Osteomalacia following gastrectomy
74	Fludrocortisone Tablets, B.P.....................	Adrenal cortical hypoplasia including Addison’s disease
Total adrenalectomy
75	Fluorouracil Sodium...................................	Treatment in malignant neoplasia
76	Fluoxymcsterone Tablets, B.P..................	Eunuchism
Eunuchoidism
Carcinoma of the breast
With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Proven aplastic anaemias
77	(1) Fluphenazine Hydrochloride, B.P.	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Fluphenazine Tablets, B.P...................	Major psychoses including—
(3) Fluphenazine Enanthate.....................	Major organic psychoses
Manic psychoses
Paranoid states
Schizophrenia

78	(1) Folic Acid, B.P......................................	Cystic fibrosis
Proven folic acid deficiency
(2) Folic Acid Tablets, B.P. 5 mg.	Sprue or the sprue-like syndrome
79	Folic Acid Tablets, B.P. 0.5 mg.	Cystic fibrosis
Pregnancy
80	Framycetin Sulphate Injection.................	Sub-conjunctival injection in the treatment of serious ocular inflammation
81	Framycetin Sulphate Tablets....................	Bowel sterilization preparatory to major surgery
82	Frusemide Tablets, B.P..............................	Fluid retention associated with heart failure, cirrhosis of the liver or nephrotic syndrome
Fluid retention associated with other conditions and not responding to thiazides
83	Galactomin Formula No. 17.....................	With the written authority of the Director-General—
Galactosaemia
Conditions needing an extreme restriction of lactose in the diet of a patient under the age of four years
84	Galactomin Formula No. 19.....................	With the written authority of the; Director-General, glucose-gnlactose malabsorption
85	Gentamicin Sulphate..................................	Any disease or condition in a patient receiving treatment in or at an approved hospital

 

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
86	Glucose Indicator—Blood........................	With the written authority of the Director-General, diabetes mellitus, where blood sugar levels cannot be determined to be within a satisfactory range by urine testing
87	Goat’s Milk, Dehydrated..........................	With the written authority of the Director-General, cow’s milk allergy in children under the age of four years
88	Goat’s Milk, Whole (Sterilized)................	With the written authority of the Director-General, cow’s milk allergy in children under the age of four years
89	(1) Griseofulvin, B.P..................................	With the written authority of the Director-General, for use in severe tinea infections due to Microsporum, Trichophyton or Epidermophyton species which have been proven by laboratory examination or Wood’s Light
(2) Griseofulvin Tablets, B.P....................
90	Halibut Liver Oil Capsules.......................	Any disease or condition in a pensioner
91	Haloperidol..................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
Major psychoses including—
Major organic psychoses
Manic psychoses
Paranoid slates
Schizophrenia
92	Hydrocortisone Acetate Injection, B.P.	Infra-articular use
93	Hydrocortisone Sodium Succinate Injection	Acute medical or surgical crisis
Prophylactic therapy before, during and after surgical
procedures for patients undergoing or recently subjected to steroid therapy
94	Hydroxocobalamin Injection, B.P.	Pernicious anaemia and other proven Vitamin B-12 deficiencies
Post gastrectomy treatment
Sub-acute combined degeneration of the cord
Neuroblastoma
95	Hydroxyprogesterone Caproate...............	Carcinoma of the endometrium
Progesterone deficiency proved by hormonal assay, by lateral wall smear or by endometrial biopsy
96	Idoxuridine...................................................	Infections caused by Herpes Simplex Virus
97	Influenza Vaccine.......................................	For prophylaxis of pensioners only
98	Insect Allergen Extract—Honey Bee	With the written authority of the Director-General, severe constitutional reaction to bee stings
99	Insect Allergen Extract—Jumper Ant	With the written authority of the Director-General, severe constitutional reaction to jumper ant stings
100	Insect Allergen Extract—Paper Wasp	With the written authority of the Director-General, severe constitutional reaction to wasp stings
101	Isoniazid Tablets, B.P.	Tuberculosis
102	Isoprenaline Hydrochloride Tablets, 30 mg.	Stokes-Adams Syndrome
103	Kanamycin Sulphate Injections...............	With the written authority of the Director-General—
Infections where positive bacteriological evidence confirms that Kanamycin Sulphate is the most appropriate antibiotic
Septicaemia, including suspected septicaemia
104	Lactulose......................................................	Hepatic coma or pre-coma (chronic porto-systcmic encephalopathy)
105	Leucovorin...................................................	Antidote to folic acid antagonists
106	Levodopa.....................................................	With the written authority of the Director-General, treatment of Parkinson’s disease
107	Lignocaine Injection, B.P..........................	Cardiac arrhythmias
108	Lincomycin Hydrochloride.......................	Gram positive coceal infections where these cannot be safely and effectively treated with a penicillin Osteomyelitis
109	Liothyronine Tablets, B.P..........................	Myxoedema

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
110	Lithium Carbonate Tablets, B.P.	With the written authority of the Director-General, manic depression
111	Lofenalac....................................................	With the written authority of the Director-General, phenylketonuria
112	Lypressin Nasal Spray..............................	Diabetes insipidus
113	Maphenide Acetate....................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
114	Medroxyprogesterone Acetate Tablets, 2.5 mg.	Carcinoma of the endometrium
115	Medroxyprogesterone Acetate Tablets, 10 mg.	Carcinoma of the endometrium
Precocious puberty
116	Medroxyprogesterone Acetate Tablets, 100 mg.	Carcinoma of the breast
Carcinoma of the endometrium
Hypernephroma
117	Medroxyprogesterone Acetate Injections	Carcinoma of the endometrium
Hypernephroma
Progesterone deficiency proven by hormonal assay, by lateral wall smear or by endometrial biopsy
118	Melphalan....................................................	Treatment in malignant neoplasia
119	Mercaptopurine Tablets, B.P....................	Allergic granulomatous angiitis
Lupus erythematosus
Nephrotic syndrome
Periarteritis (Nodosa)
Treatment in malignant neoplasia
120	(1) Methandienone Tablets, B.P.	With the written authority of the Director-General—
(2) Methenolone Acetate..........................	Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
121	Methicillin Sodium, B.P. for Injection	Proven or suspected staphylococcal septicaemia
122	Methotrexate Tablets.................................	Treatment in malignant neoplasia
123	Methotrexate Injections............................	Treatment in malignant neoplasia
124	Methylprednisolone Acetate....................	With the written authority of the Director-General—
Retention Enema....................................	Colitis, ulcerative, proven by sigmoidoscopy or radiological report
Proctitis, proven by sigmoidoscopy
125	Methylprednisolone Acetate Injection	Intra-articular use
126	(1) Methyltestosterone Tablets, B.P.	Carcinoma of the breast
Eunuchism
(2) Methyltestosterone, B.P......................	Eunuchoidism
Klinefelter’s syndrome (seminiferous tubule dysgenesis)
127	Methysergide Maleate...............................	Treatment of severe recalcitrant migraine where other treatment has failed
128	Metyrapone.................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
129	Minafen........................................................	With the written authority of the Director-General, phenylketonuria
130	Minocycline Hydrochloride......................	Any disease or condition in a patient receiving treatment in or at an approved hospital
131	Morphine Sulphate, B.P., with Tacrine Tablets	Severe intractable pain
132	Mustine Hydrochloride Injection	Treatment in malignant neoplasia
133	Nalidixic Acid.............................................	Urinary tract infections where sulphonamide treatment has proved intellective and where positive bacteriological evidence shows the organism to be sensitive to nalidixic acid or where the patient is sensitive to sulphonamides
134	Nandrolone Decanoate..............................	Carcinoma of the breast
With the written authority of the Director-General—
Intermittent use for corticostcroid-induced osteoporosis

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
134—cont.	Intermittent use for patients on long-term treatment with corticosteroids
Severe osteoporosis due to proven pancreatitis Carcinoma of the breast
	135	Nandrolone Hexoxyphenyl Propionate....
With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
136	Nandrolone Phenylpropionate Injection, B.P.	Carcinoma of the breast
With the written authority of the Director-General, intermittent use for corticosteroid-induced osteoporosis
137	Neomycin Sulphate Powder.....................	With the written authority of the Director-General, use by inhalation in cystic fibrosis (mucoviscidosis)
138	Neomycin Tablets, B.P..............................	Bowel sterilization preparatory to major surgery
Encephalopathy, hepatic
Enteropathogenic E. coli infections in infants
139	Nicotinic Acid Tablets, B.P......................	Any disease or condition in a pensioner
140	(1) Nitrofurantoin Tablets, B.P................	Urinary tract infections where sulphonamide treatment has proved ineffective and where positive bacteriological evidence shows the organism to be sensitive to nitrofurantoin or where the patient is sensitive to sulphonamides
(2) Nitrofurantoin Oral Suspension
141	Nitromin.......................................................	Treatment in malignant neoplasia
142	Norethisterone Acetate, B.P.....................	Carcinoma of the breast
143	Norethisterone Tablets, B.P......................	Endometriosis
Metropathia haemorrhagica
Precocious puberty
144	Nutramigen..................................................	With the written authority of the Director-General—
Cow’s milk allergy in children under the age of four years
Cystic Fibrosis (mucoviscidosis)
Galactosaemia
Lactose intolerance
145	Oxprenolol Hydrochloride Tablets	With the written authority of the Director-General—
Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Dissecting aneurysm, aortic
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis
146	Oxprenolol Hydrochloride Injection	Idiopathic hypertrophic subaortic stenosis Right ventricular outflow tract obstruction Dissecting aneurysm, aortic
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis
147	Oxycodone Pectinate.................................	Treatment in malignant neoplasia
148	Oxymetholone............................................	With the written authority of the Director-General—
Proven aplastic anaemias
Myelosclerosis

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
149	(1) Pancreatin, B.P.....................................	Cystic Fibrosis (mucoviscidosis)
(2) Pancreatin Enzyme 4X U.S.N.F. XII	Following pancreatico-duodencetomy
	Pancreatic steatorrhoea
(3) Pancrelipase
150	Paracetamol with Codeine Phosphate and Pentobarbitone Sodium	Any disease or condition in a pensioner
151	(1) Paraffin Liquid Emulsion...................	Any disease or condition in a pensioner
(2) Paraffin Liquid Emulsion with Phenolphthalein
152	Penicillamine...............................................	With the written authority of the Director-General—
Acute heavy metal intoxication
Cystinosis
Cystinuria with calculus formation
Haemoglobinuria, paroxysmal cold
Wilson’s disease (hepatolenticular degeneration)
153	(1) Pericyazine Mesylate..........................	Any disease or condition in a patient receiving treatment in or at an approved hospital;
(2) Pericyazine
Major psychoses, including—
Major organic psychoses
Manic psychoses
Paranoid states
Schizophrenia
154	Phytomenadione Injection, 10 mg. per ml.	Antidote to anticoagulants
Haemorrhagic diathesis associated with malabsorption
155	Phytomenadione Injection, B.P.,	Antidote to anticoagulants
1 mg. in 1 ml.	Suspected cerebral trauma of the new born
Haemorrhagic diathesis associated with malabsorption
Haemorrhagic disease of the new born
156	Pituitary, Posterior Lobe, Insufflation	Diabetes insipidus
157	Pizotifen Malate.........................................	The treatment of severe migraine in a patient whose attacks of migraine do not respond to treatment by other therapeutic agents
158	(1) PK. AID I..............................................	With the written authority of the Director-General, phenylketonuria
(2) PK AID 11
159	Plasma Substitute (Polypeptide) ..	Any disease or condition in a patient receiving treatment in or at an approved hospital
160	Polyisobutylene..........................................	Ileostomy or colostomy conditions
161	Polymyxin B. Sulphate Powder...............	With the written authority of the Director-General, use by inhalation in cystic fibrosis (mucoviscidosis)
162	Polyoestradiol Phosphate.........................	Carcinoma of the breast Carcinoma of the prostate
163	Practolol Injection.....................................	Dissecting aneurism, aortic
Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Serious arrhythmias
Thyrotoxicosis
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
164	Practolol Tablets........................................	With the written authority of the Director-General—
Dissecting aneurysm, aortic
Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Serious arrhythmias
Thyrotoxicosis
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
164—cont.	no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
165	Prednisolone Sodium Phosphate Retention Enema and Suppository	With the written authority of the Director-General—
Ulcerative colitis proven by sigmoidoscopy or radiological report
Proctitis proven by sigmoidoscopy
166	(1) Prednisolone Acetate Injection	Intra-articular use
(2) Prednisolone Butyl Acetate Injection
167	Prednisolone Acetate with Phenylephrine Hydrochloride, B.P.	Corneal grafts
Uveitis
168	Prednisolone Sodium Succinate Injection	Acute medical or surgical crisis
Prophylactic therapy before, during and after surgical procedures for patients undergoing or recently subject to steroid therapy
169	Prindolol Injections....................................	Dissceting aneurysm (aortic)
Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Serious arrhythmias
Thyrotoxicosis
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
170	Prindolol Tablets.........................................	With the written authority of the Director-General—
Dissecting aneurysm (aortic)
Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Serious arrhythmias
Thyrotoxicosis
The treatment of angina in a patient who is frequently disabled by attacks of angina in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
171	Procarbazine Hydrochloride......................	Treatment in malignant neoplasia
172	(1) Prochlorperazine...................................	Meniere’s Syndrome
(2) Prochlorperazine Tablets, B.P.
173	Progesterone.................................................	Progesterone deficiency proven by hormonal assay, by lateral wall smear or by endometrial biopsy
174	Promethazine Theoclate Tablets B.P.	Vomiting in pregnancy
175	Propranolol Injection, B.P.........................	Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Dissecting aneurysm, aortic
The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents

Serious arrhythmias
Thyrotoxicosis
176	Propranolol Tablets, B.P............................	With the written authority of the Director-General—
Idiopathic hypertrophic subaortic stenosis
Right ventricular outflow tract obstruction
Dissecting aneurysm, aortic

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
176—cont.	The treatment of angina in a patient who is frequently disabled by attacks of angina, in whom no evidence of cardiac failure is found and whose attacks of angina do not respond to other therapeutic agents except other beta-adrenergic receptor blocking agents
Serious arrhythmias
Thyrotoxicosis
177	Proscillaridin.................................................	Patients intolerant of oral forms of prepared digitalis, digoxin and lanatoside C
178	Prosobee.......................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
179	Pyrazinamide...............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
180	(1) Pyridostigmine Injection, B.P.	Myasthenia gravis
(2) Pyridostigmine Tablets, B.P.
181	Pyridoxine Hydrochloride Tablets	Homocystinuria
Radiation sickness
Treatment and prophylaxis of peripheral neuritis caused or likely to be caused by isoniazid therapy
Sideroblastic (refractory anaemia)
Proven pyridoxine responsive anaemia
With the written authority of the Director-General, primary hyperoxaluria
182	Riboflavine Tablets....................................	Any disease or condition in a pensioner
183	Senna Fruit Extract (standardised)	Any disease or condition in a pensioner
184	Similac Isomil..............................................	With the written authority of the Director-General,
Galaetosaemia
Homoeystinuria
Lactose intolerance
Milk allergy in children under the age of four years
185	Sobee.............................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
186	(1) Sodium Aminosalicylate Tablets, B.P.	Tuberculosis
(2) Sodium Aminosalicylate Injection
(3) Sodium Aminosalicylate Cachets
(4) Sodium Aminosalicylate Granules
(5) Sodium Aminosalicylate with Isoniazid, B.P.
187	(1) Sodium Fusidate...................................	With the written authority of the Director-General,
(2) Dietltanolamine Fusidate	for use in combination with another antibiotic in the treatment of serious staphylococcal infections confirmed by bacteriological evidence
188	Soyalac.........................................................	With the written authority of the Director-General—
Galactosaemia
Homocystinuria
Lactose intolerance
Milk allergy in children under the age of four years
189	Spironolactone Tablets, B.P......................	With the written authority of the Director-General—
To supplement other diuretics when these have proved inadequate
Myasthenia gravis
Primary hyperaldosteronism

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
190	Stanolone......................................................	Carcinoma of the breast
With the written authority of the Director-General—
Intermittent use for corticosteroid-induced osteoporosis
Intermittent use for patients on long-term treatment with corticosteroids
191	Stanozolol.....................................................	With the written authority of the Director-General—
Intermittent use for corticostcroid-induced osteoporosis
Intermittent use for patients on a long-term treatment with corticosteroids
192	Stilboestrol Diphosphate...........................	Carcinoma of the prostate
193	Streptokinase...............................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
194	Sulphasalazine.............................................	Ulcerative colitis
195	(1) Surgical Cement...................................	Ileostomy or colostomy conditions
(2) Surgical Cement Solvent.....................	For use with surgical appliances
196	(1) Testosterone Propionate, B.P. with Testosterone Phenylpropionate, B.P. and Testosterone Isocaproate	Eunuchoidism
Eunuchism
Klinefelter’s syndrome (seminiferous tubule dysgenesis)
		(2) Testosterone Propionate, B.P. with Testosterone Phenylpropionate, B.P., Testosterone Isocaproate and Testosterone Decanoate	Carcinoma of the breast
(3) Testosterone Implants, B.P.
(4) Testosterone Enanthate
(5) Testosterone Propionate Injection, B.P.
197	Tetanus Antitoxin, B.P. (Bovine)	Patients who have previously received an injection of equine serum
198	Thiamine Hydrochloride Tablets, B.P.	Any disease or condition in a pensioner
199	Thiethylperazine Maleate Tablets and Suppositories	Radiation sickness
Nausea resulting from cytotoxic therapy
200	(1) Thioridazine...........................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
(2) Thioridazine Tablets, B.P.
Major psychoses including—
Major organic psychoses
Manic psychoses
Paranoid states
Schizophrenia
Severe conduct disorders of children
201	Thyrotropin..................................................	Any disease or condition in a patient receiving treatment in or at an approved hospital
202	Tragacanth, Indian (Gum Karaya)	Ileostomy or colostomy conditions
203	Tretamine.....................................................	Treatment in malignant neoplasia
204	Triamcinolone Acetonide Injection	With the written authority of the Director-General, treatment of keloids
205	(1) Trifluoperazine Hydrochloride,	Any disease or condition in a patient receiving
B.P.	treatment in or at an approved hospital
(2) Trifluoperazine Tablets, B.P.	Major psychoses including—
Major organic psychoses
Manic psychoses
Paranoid states
Schizophrenia
206	Triglyde.........................................................	With the written authority of the Director-General, proven malabsorption
207	Trimethoprim with Sulphamethoxazole	Respiratory tract infections or urinary tract infections where positive bacteriological evidence shows trimehoprim with sulphamethoxazole to be effective
Ocular surgery

Fifth Schedule—continued

First Column	Second Column	Third Column
Item No.	Pharmaceutical Benefit	Purpose for which, and the Conditions subject to which, the Pharmaceutical Benefit may be prescribed (including any restrictions as to the persons for whose treatment it may be prescribed) for supply under Part VII. of the Act
208	(1) Vinblastine Sulphate............................	Treatment in malignant neoplasia
(2) Vincristine Sulphate
209	Vinyl Pyrrolidone and Vinyl Acetate with Benzocaine Aerosol Spray	Ileostomy or colostomy conditions
210	(1) Viomycin Sulphate..............................	Tuberculosis
(2) Viomycin Sulphate Injection, B.P.
211	Vitamin A with Thiamine Hydrochloride, Riboflavine, Nicotinamide, Ascorbic Acid and Vitamin D Tablets and Capsules	Any disease or condition in a pensioner

THE SCHEDULES

FIRST SCHEDULE. Regulation 2.

Amendments of the First Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. After item 114 insert the following item:—

“ 114a. Cycloserine Tablets ”.

2. After item 161 insert the following item:—

“ 161a. Edrophonium Injection ”.

3. After item 243 insert the following items:—

“ 243a. Levorphanol Injection

“ 243b. Levorphanol Tablets ”.

4. Omit item 249.

5. After item 297 insert the following item:—

“ 297a. Morphine Sulphate Tablets ”.

SECOND SCHEDULE Regulation 3.

Amendments of the Second Schedule to the National Health (Pharmaceutical Benefits) Regulations

• 1.

  After item 8 insert the following item:—

“ 8a. Aminogran............................... __ ”.

• 2.

  After item 53 insert the following item:—

“ 53a Dextrose Polymer................... __ ”.

3. Omit from item 64 “ Oxyphenisatin Acetate with Dioctyl Sodium Sulphosuccinate B.P.C.” (in the third column).

4. Omit item 132.

5. After item 154 insert the following items:—

“ 154a	PK AID I..................................	__	”.
154b	PK AID II.................................	__	”.

6. Omit item 160, insert the following item:—

“ 160 Prednisolone Acetate............. Prednisolone Acetate with Phenylephrine Hydrochloride B.P.”.

THIRD SCHEDULE Regulation 4.

Amendments of the Third Schedule to the National Health (Pharmaceutical Benefits) Regulations

1. After item 28 insert the following item:—

“ 28a. Aminogran ”.

2. After item 67 insert the following item:—

“ 67a. Cephalexin Monohydrate ”.

3. Omit item 98.

4. After item 105 insert the following items:—

“ 105a. Dextrose Polymer

“ 105b. Diazoxide ”.

5. After item 122 insert the following item:—

“ 122a. Epicillin ”.

6. After item 185 insert the following item:—

“ 185a. Lactulose ”.

7. Omit item 249.

8. After item, 284 insert the following items:—

“ 284a. Pizotifen Malate

“ 284b. PK AID I

“ 284c. PK AID II ”.

9.After item 296 insert the following item:—

“ 296a. Prindolol ”.

10. Omit item 326.

11. Omit item 387.

                     

Printed by Authority by the Government Printer of the Commonwealth of Australia